Published online Nov 26, 2021. doi: 10.12998/wjcc.v9.i33.10161
Peer-review started: April 2, 2021
First decision: July 3, 2021
Revised: July 13, 2021
Accepted: September 6, 2021
Article in press: September 6, 2021
Published online: November 26, 2021
Processing time: 233 Days and 19.6 Hours
Studies have confirmed that type 2 diabetes mellitus (DM) can cause cognitive impairment. The mechanism is not clear. Dipeptidyl peptidase-4 (DPP4) may be involved in this process.
The main problem in this study is whether cognitive impairment exists in pregnant women with gestational DM (GDM) and whether it is related to DPP4. This has a great impact on the physical and mental health of pregnant women with perinatal GDM and the health of the fetus.
Objective to study the cognitive function of pregnant women with GDM, and to find out whether the pathway is related to DPP4.
They were divided into three groups: GDM group, healthy pregnant group and control group. Women in the three groups were scored with Montreal Cognitive Assessment. Venous blood was collected from women in each group, serum was separated, and serum indexes such as DPP4, interleukin-6, and 8-iso-prostaglandin
Compared with the other two groups, the GDM group had cognitive impairment, especially memory impairment. DPP4 may induce the change of BDNF by promoting oxidative stress and inflammatory response.
GDM can lead to cognitive dysfunction in pregnant women, mainly manifested as memory loss. DPP4 may be involved in this process.
Perinatal cognitive decline is worth our attention, especially in GDM pregnant women. How to prevent and treat is the key. Whether DPP4 can be used as a therapeutic target needs further study.